Pulmonary Hypertension: Intensification and Personalisation of Combination Rx - Trial NCT05825417
Access comprehensive clinical trial information for NCT05825417 through Pure Global AI's free database. This Phase 4 trial is sponsored by Sheffield Teaching Hospitals NHS Foundation Trust and is currently Not yet recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sheffield Teaching Hospitals NHS Foundation Trust
Timeline & Enrollment
Phase 4
Apr 01, 2023
Jan 01, 2026
Primary Outcome
Right Ventricular Stroke Volume (RVSV) flow on each therapy measured by MRI RSVS (flow) on each therapy measured by MRI
Summary
The goal of this clinical trial is to evaluate the capacity of implantable/remote technology
 for early evaluation of drug therapies in patients with pulmonary arterial hypertension
 (PAH). The main question it aims to answer is whether structured changes in clinical therapy
 will be detectable using implanted regulatory approved devices. Participants will will be
 implanted with approved medical devices and will enter into a study of approved drugs to
 assess physiology, activity and patient reported quality-of-life (QoL) outcomes. Researchers
 will compare two therapeutic strategies in each individual patient to see if the study design
 provides enough evidence to personalise drug treatment plans
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05825417
Non-Device Trial